Source: Applied Clinical Trials

Kayentis: Kayentis Forges Ahead on New eCOA Service Projects

Kayentis has announced it is forging ahead on five new eCOA service projects with Emerging BioPharma companies. The projects Kayentis is collaborating on involve phase II and III clinical studies in therapeutic areas addressing unmet needs in areas like oncology, immune disorders, and rare disea

Read full article »
Est. Annual Revenue
$5.0-25M
Est. Employees
100-250
Guillaume Juge's photo - President & CEO of Kayentis

President & CEO

Guillaume Juge

CEO Approval Rating

73/100

Read more